Biograph VK10
Siemens Medical Solutions USA, Inc. • Radiology • 01/12/2024
Device Purpose
The Biograph VK10 is a hybrid PET/CT imaging system designed to provide integrated anatomical and metabolic information for enhanced diagnosis, staging, and treatment planning in oncology, neurology, and cardiology. It employs X-ray computed tomography for anatomical detail and positron emission tomography with an air-cooled SiPM detector system to map radiopharmaceutical distribution, offering improved cost-effectiveness and patient accessibility while maintaining robust, quantitatively verified performance.
Summary
The Siemens Biograph VK10 is a hybrid medical imaging system combining X-Ray Computed Tomography (CT) and Positron Emission Tomography (PET) functionalities. Its primary purpose is to provide clinicians with co-registered anatomical (CT) and metabolic/physiologic (PET) information for comprehensive diagnostic evaluations in oncology, neurology, and cardiology. The CT component utilizes X-ray transmission data to reconstruct cross-sectional body images, while the PET subsystem images the distribution of administered radiopharmaceuticals to assess molecular and physiological functions, using an air-cooled Silicon Photomultiplier (SiPM) based detector system. This dual-modality approach allows for precise anatomical localization of metabolic activity, with the CT data also used for rapid attenuation correction in PET studies, and the system supports independent CT or PET imaging. The Biograph VK10 incorporates features from predecessor systems, such as the Biograph Vision, but introduces a more cost-effective SiPM PET system and integrates commercially available "go. systems" for its CT component to enhance workflows and patient interaction. Key updates include software combining functionalities for patient management, scan control, and image processing compliant with DICOM standards, and an increased patient handling system weight limit for bariatric accessibility. Performance testing for the PET subsystem, conducted according to NEMA NU 2:2018 standards, confirmed that the Biograph VK10 met all predetermined acceptance criteria for resolution, sensitivity, count rate, co-registration accuracy, time-of-flight resolution, and image quality. The CT component also supports low-dose lung cancer screening.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of the air-cooled SiPM PET system in the Biograph VK10 specifically compare to the previous Biograph Vision's PET system under various clinical radiotracer imaging scenarios, beyond the NEMA NU 2:2018 standard tests?; What are the specific improvements in workflow and patient interaction facilitated by the integration of the "go. systems" CT component, and how do these translate to efficiency or patient comfort?; What are the technical specifications and performance differences of the varying PET axial Field of View (FoV) configurations and different CT configurations mentioned as part of the Biograph VK10's scalability?; Given the increased weight limit for the patient handling system, what considerations were made for image quality and PET attenuation correction accuracy in bariatric patients?; Beyond meeting acceptance criteria, how do the quantitative NEMA NU 2:2018 performance metrics of the Biograph VK10 (e.g., TOF resolution, sensitivity for Axial FoV 1 vs. FoV 2) directly impact its diagnostic capabilities for specific low-uptake lesions or dynamic studies compared to its predicate?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of OBOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, ML-BOM, SaaSBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly